SPL23-2

DB17866ExperimentalGene Therapies

SPL23-2 is an antisense oligonucleotide (ASO) targeting the W1282X nonsense mutation associated with a severe form of cystic fibrosis.

Code names
SPL23-2

What you can answer from here — as of April 02, 2025

1+ReferenceStructured and connected to the statements they support
Sign in

Which companies are running trials of SPL23-2, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In